glp-1 ghrelin Is a glucagon‐like peptide‐1 secretagogue? - Ueno - 2016 - Journal of Diabetes Investigation Characterizing ghrelin's role in dysregulating

Description

Quick Answer: GLP-1 medications show clinically meaningful average weight loss in large-scale peer-reviewed trials - approximately 14.9% for semaglutide (STEP 1) and up to 20.9% for tirzepatide (SURMOUNT-1) under trial conditions

There is no reliable timeline, and it varies a lot from person to person

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

A GLP-1-kiegsztk idelisak lehetnek, ha: Szeretn tmogatni az egszsges glkz- s tvgy egyenslyt Termszetes mdon vagy GLP-1 gygyszeres kezels mellett kezelik a testslyt Energiacskkenst vagy tkezs utni fradtsgot tapasztalnak Meg akarja tartani a sovny izomzatot a kalriacskkents sorn rtkeljk a termszetes, tudomnyos alapokon nyugv wellness megoldsokat Mirt vlassza a Naturecan GLP-1 kiegsztket A Naturecan-nl tlmutatunk a trendeken, klinikailag altmasztott formulkat, fggetlen tesztelst s egyrtelm tlthatsgot biztostunk